A phase I trial of BCL2 antisense drug G3139 (Genta, Inc.) delivered by continuous intravenous infusion alone and in combination with weekly paclitaxel Meeting Abstract
| Authors: | Morris, M. J.; Tong, W. P.; Cordon-Cardo, C.; Drobnjak, M.; Kelly, W. K.; Slovin, S. F.; Terry, K. L.; DiPaola, R. S.; Rosen, N.; Scher, H. I. |
| Abstract Title: | A phase I trial of BCL2 antisense drug G3139 (Genta, Inc.) delivered by continuous intravenous infusion alone and in combination with weekly paclitaxel |
| Meeting Title: | 1999 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Development, and Clinical Validation |
| Journal Title: | Clinical Cancer Research |
| Volume: | 5 |
| Issue: | 11 Suppl. |
| Meeting Dates: | 1999 Nov 16-19 |
| Meeting Location: | Washington, DC |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 1999-11-01 |
| Start Page: | 3732s |
| End Page: | 3733s |
| Language: | English |
| ACCESSION: | WOS:000083945700018 |
| PROVIDER: | wos |
| PUBMED: | 10590781 |
| Notes: | Meeting Abstract: 17 -- Source: Wos |
Citation Impact
